We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GlymaxX®

News List

ValenzaBio Partners with ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX® b3cnewswire
July 28, 2021
ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology.
ProBioGen Inks Next Commercial GlymaxX® License with Roche b3cnewswire
January 16, 2020
ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.
ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement b3cnewswire
May 24, 2019
ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement